Osteogenesis imperfecta: Lifelong management is imperative and feasible

Joint Bone Spine

Volumn 68, Issue 2, 2001, Pages 125-129

  Chevrel, Guillaume ^a   Meunier, Pierre Jean ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bisphosphonates; Bone density measurement; Osteogenesis imperfecta

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; VITAMIN D;

BONE DEFORMATION; BONE DENSITY; BONE INJURY; BONE PAIN; BONE TURNOVER; CALCIUM DEFICIENCY; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FOLLOW UP; FRACTURE; HISTOPHOTOMETRY; HUMAN; OSTEOGENESIS IMPERFECTA; REVIEW; VITAMIN D DEFICIENCY;

EID: 0035070718     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(01)00256-1     Document Type: Review

References (42)

1. Mutations in fibrillar collagens (type I, II, III, XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels
2. L'ostéogenèse imparfaite: Des mutations aux phénotypes
3. Genetic heterogeneity in osteogenesis imperfecta
4. Osteogenesis imperfecta: An expanding panorama of variants
5. Les micromélies congénitales: Achondroplasie et dystrophie périostale
6. Les hommes de verre
7. Blue sclerae in osteogenesis imperfecta
8. On the paradoxically high relative prevalence of osteogenesis imperfecta type III in the Black population of South Africa
9. Type V osteogenesis imperfecta
10. Mutation analysis of coding sequences for type I procollagen in individuals with low bone density
11. Extension of phenotype associated with structural mutations in type I collagen: Siblings with juvenile osteoporosis have an alpha2(I)Gly436- > Arg substitution
12. Causes of death in osteogenesis imperfecta
13. Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta
14. Basilar invagination in osteogenesis imperfecta and related-osteochondrodysplasias: Medical and surgical management
15. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta
16. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis
17. Bone density in osteogenesis imperfecta may well be normal
18. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta
19. Bone mineral density in osteogenesis imperfecta
20. Bone mineral density in children with mild osteogenesis imperfecta
21. Hypercalciuria in children severely affected with osteogenesis imperfecta
22. Hypercalciuria in osteogenesis imperfecta: A follow-up study to assess renal effects
23. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta
24. Collagen-derived markers of bone metabolism in osteogenesis imperfecta
25. Osteogenesis imperfecta: Bone turn-over, bone density, and ultrasound parameters
26. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
27. Effect of pamidronate on bone turnover and IGF-I in type I osteogenesis imperfecta
28. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta
29. Systemic treatment of osteogenesis imperfecta
30. Are drugs helpful in adults with osteogenesis imperfecta
31. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta
32. Is APD a promising drug in the treatment of severe osteogenesis imperfecta?
33. Treatment of osteogenesis imperfecta with the bisphosphonate olpodronate (dimethylaminohydroxypropylidene bisphosphonate)
34. Intravenous pamidronate treatment in osteogenesis imperfecta
35. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients
36. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age
37. Osteogenesis imperfecta after the menopause
38. Ostéogenèse imparfaite. Indications thérapeutiques chez l'enfant
39. Ostéogenèse imparfaite de l'enfant
40. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta